Universe Pharmaceuticals Inc income statement

In fiscal 2025, Universe Pharmaceuticals Inc reported revenue of $17.86bn, down 22.4% on the year before, operating income of −$2.92bn (a -16.3% margin) and net income of −$3.67bn, or −$8.06 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Universe Pharmaceuticals Inc: income statement, annual
Fiscal year	2019Sept 2019	2020Sept 2020	2021Sept 2021	2022Sept 2022	2023Sept 2023	2024Sept 2024	2025Sept 2025
Revenue	0.0	0.0	0.0	0.0	32.3	23.0	17.9
Cost of revenue	0.0	0.0	0.0	0.0	22.0	17.0	11.6
Gross profit	0.0	0.0	0.0	0.0	10.3	6.1	6.3
Research and development	0.0	0.0	0.0	0.0	4.9	3.0	0.7
General and administrative	0.0	0.0	0.0	0.0	2.6	2.9	3.7
Operating income	0.0	0.0	0.0	−0.0	−4.0	−8.0	−2.9
Interest expense	0.0	0.0	0.0	0.0	0.2	0.3	0.3
Income before tax	0.0	0.0	0.0	−0.0	−4.3	−8.1	−3.7
Income tax	0.0	0.0	0.0	0.0	2.3	0.6	—
Net income	0.0	0.0	0.0	−0.0	−6.6	−8.7	−3.7
Diluted EPS	$2.82	$2.82	$3.58	−$1309.11	−$1089.21	−$626.96	−$8.06
Diluted shares (average)	3m	3m	3m	—	6m	14m	—
EBITDA	0.0	0.0	0.0	−0.0	−3.5	−7.5	−2.4

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: UPC vs VTRS HLN vs UPC BHC vs UPC

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Universe Pharmaceuticals Inc's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Universe Pharmaceuticals Inc.